(Q34789894)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586175%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

review article

1 reference

title

Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586175%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586175%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Brian M Feldman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586175%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Ann M Reed

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586175%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Lauren M Pachman

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586175%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

English

0 references

publication date

1 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586175%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586175%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586175%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

9631

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586175%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

2201-2212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586175%20AND%20SRC:MED&resulttype=core&format=json

Classification and treatment of the juvenile idiopathic inflammatory myopathies

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

The heterogeneity of juvenile myositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

The incidence of juvenile dermatomyositis: results from a nation-wide study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

The role of genetic factors in autoimmune disease: implications for environmental research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Increased frequency of HLA-B8 in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Molecular genetic studies of major histocompatibility complex genes in children with Juvenile dermatomyositis: Increased risk associated with HLA-DQA1∗0501

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Childhood polymyositis: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Dermatomyositis, polymyositis, and Coxsackie-B-virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Dermatomyositis-like syndrome due to toxoplasma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Genetic and environmental risk factors for idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Dermatomyositis (systemic angiopathy) of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Interleukin-1? expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: Important pathogenic features independent of inflammatory cell clusters in muscl

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: impact of duration of untreated disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Chimerism in children with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Is it really myositis? A consideration of the differential diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Inflammatory myopathies in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Polymyositis and dermatomyositis (first of two parts)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Polymyositis and dermatomyositis (second of two parts)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary--clinical characteristics and disease course of 44 patients with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Characteristics of juvenile dermatomyositis in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Juvenile dermatomyositis. Pathophysiology and disease expression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Patterns of calcification in childhood dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Staphylococcal infections in childhood dermatomyositis--association with the development of calcinosis, raised IgE concentrations and granulocyte chemotactic defect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Course of treated juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Abdominal pain in a girl with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Pneumatosis intestinalis in dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Juvenile dermatomyositis presenting with anasarca: A possible indicator of severe disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Spontaneous pneumomediastinum and dermatomyositis may be a not so rare association: report of a case and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Study of subcutaneous fat in children with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Childhood acquired lipodystrophy: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Amyopathic dermatomyositis: retrospective review of 37 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Macrophagic Myofasciitis in Childhood: A Controversial Entity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

CAPN3 mutations in patients with idiopathic eosinophilic myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

A novel autoantibody to a 155-kd protein is associated with dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

International consensus on preliminary definitions of improvement in adult and juvenile myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Methotrexate treatment of recalcitrant childhood dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Cyclosporin in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Reversal of chronic polymyositis following intravenous immune serum globulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Treatment of dermatomyositis with intravenous gammaglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Prednisone and azathioprine for polymyositis: long-term followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Decreased aerobic capacity in children with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Late progression in dermatomyositis in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021

Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960955-1

7 January 2021